Conference Coverage
Conference Coverage
Add-on nab-paclitaxel extends survival in metastatic pancreatic cancer
Major Finding: Median overall survival in patients with metastatic pancreatic cancer increased from 6.7 months on gemcitabine to 8.5 months on nab...
Conference Coverage
Interferon plus entecavir may tame chronic HBV
Major Finding: Patients with chronic hepatitis B who were treated with entecavir and pegylated interferon alfa-2a had a greater decline in HBV DNA...
Conference Coverage
Ribavirin dose reduction, erythropoietin combat HCV anemia
Major Finding: In cirrhotic and noncirrhotic patients treated with boceprevir, pegylated interferon alfa-2b, and ribavirin, 57% of patients with...
Conference Coverage
Avatrombopag reduces preprocedure platelet needs in chronic liver disease
Major Finding: In a study cohort with a second-generation formulation of avatrombopag, 9 of 21 patients on a 10-mg daily dose (42.9%) had a...
Conference Coverage
Tenofovir alone suffices against lamivudine-resistant hepatitis B
Major Finding: In a phase IIIb randomized study, 89% of lamivudine-resistant patients with HBV who received tenofovir alone met the primary end...
Conference Coverage
Triple therapy has poor safety in cirrhotic hepatitis C
Major Finding: At 16 weeks of therapy, 45% of treatment-experienced cirrhotic patients on a combination of telaprevir, pegylated interferon, and...
Conference Coverage
Investigational HCV Regimens Ditch the Interferon
Conference Coverage
Pneumonia Prevalence Highest of Health Care-Associated Infections
Major Finding: The overall prevalence of health care–associated infections among hospitalized patients nationwide was 4%.Data Source: Preliminary...
Conference Coverage
Bedside Tools to ID Severe C. difficile Fall Short
Conference Coverage
Weight Loss After Roux-en-Y Tied to Type 2 Diabetes Reversal
Major Finding: Up to 73% of obese patients with type 2 diabetes had normalized blood glucose after Roux-en-Y gastric bypass surgery.Data Source:...